CURRETAB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Curretab, and when can generic versions of Curretab launch?
Curretab is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in CURRETAB is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Curretab
A generic version of CURRETAB was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CURRETAB?
- What are the global sales for CURRETAB?
- What is Average Wholesale Price for CURRETAB?
Summary for CURRETAB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Clinical Trials: | 2 |
| DailyMed Link: | CURRETAB at DailyMed |
Recent Clinical Trials for CURRETAB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Indiana University | Phase 2 |
| Translational Breast Cancer Research Consortium | Phase 2 |
| Gynecologic Oncology Group | Phase 2 |
US Patents and Regulatory Information for CURRETAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | CURRETAB | medroxyprogesterone acetate | TABLET;ORAL | 085686-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
